(eQTL) analyses showed that the risk allele (G) of rs17144046 was significantly associated with increased expression of GATA3 (P = 0.017). Reported studies indicated a close correlation between GATA3 and BPH pathogenesis and progression.
Conclusions: Rs17144046 located near GATA3 was significantly associated with BPH/LUTS in three independent populations, but did not reach a stringent GWAS significance level. Genetic variants of GATA3 may play a role in the inherited susceptibility and etiology of BPH/LUTS. Further research in this area is needed.
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| BACKGROUND
Benign prostatic hyperplasia (BPH) is common in the aging male with a histopathological prevalence in 80% of men by age 80.
1 BPH contributes to bladder outlet obstruction, leading to bothersome lower urinary tract symptoms (LUTS). BPH is associated with complications such as urinary tract infections, acute urinary retention, hematuria, and lithiases. One third of men with BPH ultimately undergo medical and/or surgical interventions. In addition, BPH has been associated with increased risks of mortality, depression, and diminished health-related quality of life, as well as with billions of U.S.
dollars in annual health expenditures. 2 These societal and financial burdens are becoming exacerbated with the shift towards an older age distribution of the population in economically developed countries.
The etiology of BPH is not well understood. Increasing age and the extended presence of testicular androgens are consistent risk factors.
BPH has long been considered a product of androgen and estrogen action upon an aging prostate. 3 However, it is now clear that multiple mechanisms contribute to the disease. 4 Comorbidities such as obesity and type 2 diabetes mellitus appear to contribute to disease progression, potentially contributing to cell proliferation and resistance to current therapies. 5 Metabolic syndrome is associated with BPH, LUTS, and prostate growth. 6 In addition, inflammatory conditions are also associated with increased incidence of BPH. [7] [8] [9] In addition to environmental risks, family and twin studies have provided strong evidence for genetics as an important risk factor for developing BPH. One study reported a 66% lifetime risk of requiring surgical intervention for BPH among first degree male relatives of case probands, which was fourfold higher than those without a similar family history. 10 A twin study indicated that the relative risk for BPH for monozygotic twins was 3. 15 Inclusion and exclusion criteria for REDUCE were described in a previous study. 16 The definitions of BPH/LUTS were: (a) IPSS score ≥ 8 (moderate symptoms, ≥25 were excluded due to the exclusion criteria of REDUCE) at study entry, or (b) prostate volume ≥30 mL. A total of 3103 men of European descent who consented for genetic studies with genotype data were included. It should be noted that only baseline data were used, and the effects of dutasteride on LUTS were not investigated.
The characteristics of the study population from CLUE II were described in a previous publication. 17 Briefly, this was a community cohort with 32 898 volunteers who were recruited in Washington Index ≥15 (high-moderate to severe symptoms). A total of 568 men met these criteria, as well as a group of age-and race-paired control men (n = 568) who were also included. All study protocols were approved by the institutional review board at each research site, and all participants provided written informed consent.
| SNP genotyping and quality control (QC) in the GWAS stage
SNPs were genotyped using the Illumina HumanOmniExpress 21 A posterior probability of >0.90 was applied to call genotypes during imputation and the same QC procedure for excluding genotyped SNPs was applied to imputed SNPs.
| SNP genotyping and QC in confirmation stages
Selected SNPs were genotyped using the Sequenom iPLEX system (San Diego, CA). All plates contained an asymmetric distribution of control samples (CEPH for positive control and water for negative control). Two percent of the samples were randomly selected to be duplicated. The concordance rates for all SNPs were calculated among duplicates.
| Statistical analyses and eQTL analyses
A logistic regression model was used to evaluate the association between each SNP and BPH/LUTS using Plink 1.07. The metaanalysis of the two GWAS datasets (CLUE II and REDUCE) was performed using GWAMA. 22 
| RESULTS
The demographic information of the study populations is shown in Table 1 . The detailed characteristics of the CLUE II study population and Finnish population have been described in previous studies. 17, 19, 20 To initially identify candidate genetic variants in the form of SNPs that may be associated with BPH/LUTS, we performed GWAS Fig. S1 ). The Table 2 .
From the combined GWAS data, a total of 772 SNPs were selected for confirmation in the Finnish BPH/LUTS population based on three strategies (Supplementary Table 3 shows the SNPs that were significantly associated with BPH/LUTS at the confirmation stage after Bonferroni correction for multiple testing (<0.05/772 = 6.5 × 10 −5 ). Results from the metaanalysis of the two GWASs and the confirmation study of these two SNPs are also shown in Table 3 . A regional plot shows that rs17144046 has very mild linkage disequilibrium with SNPs located at GATA3 or other nearby genes (Fig. 3 ).
Another SNP, rs943587, was observed to be significantly associated with BPH/LUTS in the confirmation study (OR = 1.63, 95%CI: 1.30-2.03, P = 1.60 × 10
−5
). However, the locus was no longer significant or marginally significant after meta-analysis (OR = 1.11, P -meta = 0.80) due to the different directions of ORs in REDUCE and CLUE II (Table 3 and Fig. 2) . Further studies are required to fully answer this question.
We did observe a SNP near GATA3 that was marginally statistically significant, and have thus nominated this gene as an interesting candidate gene worthy of further study. GATA3 belongs to the GATA family of transcription factors that contain two GATA-type zinc fingers. GATA3 is expressed in a range of human tissues, including cells from all three embryonic germ layers. Deletion of the gene is embryonic lethal in mice and abnormalities are an underlying cause of hypoparathyroidism, sensorineural deafness and renal anomalies (HDR) syndrome in humans. 25, 26 GATA3 has a broad range of described interactions with other transcription factors. It has been reported to interact with androgen receptors as well as with estrogen receptors-α and -β, all of which have been implicated in BPH pathogenesis and progression. 27, 28 GATA3 also interacts with nuclear factor-kappaB (NF-κB) to regulate inflammation. This transcription factor is thus known to be a key player in the major pathways implicated in BPH, providing a strong rationale to suspect that this GWAS finding has a biological basis.
29
GATA2 and GATA3 are expressed in the mouse prostate, localizing to the nuclei of luminal epithelial cells. 30 The human protein atlas There are several important limitations to our study. In spite of including nearly 5000 men, the sample size remains relatively small, limiting our ability to detect more subtle genetic associations, particularly in subsets of affected men. As discussed above, a particularly important limitation is the variability of the criteria used to determine affected status among the various study populations.
Such variability in phenotype likely reduced our power to detect significant associations substantially. In addition, our study population was primarily of European background, thus reducing the generalizability of our results to men of other ancestries. In the future, larger studies with more precise and uniform criteria for affected status will be needed to fully elucidate the role of genetic variation in BPH/LUTS etiology. In the meantime, our novel results provide an important basis for additional studies of the role of GATA3 in normal and pathobiology of the prostate. Isaacs. In addition, this study is partially supported by a National
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